INTEC PHARMA LTD.
NTEC evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Lead Asset:
- ap-cannabinoids (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NTEC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
ap-cannabinoids (Phase 1)
Next Catalyst
—
Tracking 1 pipeline candidate · 2 clinical trials for INTEC PHARMA LTD..
Run INTEC PHARMA LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTEC PHARMA LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is INTEC PHARMA LTD.'s lead drug candidate?
INTEC PHARMA LTD.'s most advanced tracked candidate is ap-cannabinoids (Phase 1) for Various pain indications.
Who is the CEO of INTEC PHARMA LTD.?
William B. Hayes is the chief executive officer of INTEC PHARMA LTD. (NTEC).
What therapeutic areas does INTEC PHARMA LTD. focus on?
INTEC PHARMA LTD. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.